GLOBAL CLIMATE
TO TRAVEL
MEDICINE RESEARCH SCIENCE
New bioprosthetic valve for TAVR fails to demonstrate non-inferiority
Vondestei4760
NEW YORK – October 15, 2020 – In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.
Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. The study was also published simultaneously in Circulation.
The SCOPE II trial was designed to compare the clinical outcomes of the ACURATE neo and CoreValve Evolut valves. A total of 796 patients aged 75 years or older with symptomatic severe aortic stenosis and an indication for transfemoral TAVR as agreed by the Heart Team were recruited at 23 tertiary heart valves centers in Denmark, France, Germany, Italy, Spain and the United Kingdom. Participants were randomly assigned (1:1) to receive treatment with the ACURATE neo (n=398) or the CoreValve Evolut devices (n=398).
The primary safety endpoint, powered for non-inferiority of the ACURATE neo valve using a noninferiority margin of 6%, was the composite of all-cause mortality or stroke at 12 months. The primary efficacy endpoint, powered for superiority, was new permanent pacemaker implantation at 30 days. Secondary endpoints included clinical efficacy and safety endpoints at 30 days and 12 months.
In the intention-to-treat analysis, death or stroke at one year was 15.8% in the ACURATE neo group compared to 13.9% in the CoreValve Evolut group, while in the per-protocol analysis it was 15.3% vs. 14.3%. Noninferiority of the ACURATE neo was not met for the primary endpoint in the intent-to-treat analysis, while it was met in the per-protocol analysis. Based on the prespecified statistical plan, due to these inconsistent results, non-inferiority was not established for the primary endpoint.
New pacemaker implantation at 30 days was 10.5% with ACURATE neo compared to 18.0% with CoreValve Evolut (Risk Difference -7.5%, 95% CI -12.4–2.60, P= 0.0027). Cardiac death at 30 days (2.8% vs 0.8%, p=0.03) and one year (8.4% vs 3.9%, p=0.01) was greater in the ACURATE neo group. The rate of moderate-severe aortic regurgitation was 9.6% vs 2.9% (P<0.0001) at 30 days and 4.0% vs. 3.3% (P<0.0001) at one year.
"TAVR with the ACURATE neo valve did not meet noninferiority compared with the CoreValve Evolut bioprosthesis with respect to a composite of death or stroke at one year," said Corrado Tamburino, MD, PhD, Division of Cardiology at C.A.S.T. (Centro Alte Specialità e Trapianti) Policlinico – University of Catania, Catania, Italy. "In a secondary analysis with limited statistical power, cardiac death was increased at one year in patients who received the ACURATE neo valve. The two valves also differed with respect to technical characteristics such as degree of aortic regurgitation and need for new permanent pacemaker implantation."
The SCOPE II trial was sponsored by the Center for European Research Initiatives in Cardiovascular Medicine (CERIC). Prof. Tamburino reported the following disclosures: speaker fees from Medtronic.
The Cardiovascular Research Foundation (CRF) is one of the world's leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer medical advances and educated doctors on the latest treatments for heart disease. CRF is comprised of the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Now in its 32nd year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.
For more information, visit http://www.crf.org and http://www.tctconference.com.
PHYS-ORG RESEARCH
PHYS-ORG RESEARCH SPACE
MIXED PHYS-ORG RESEARCH
Earth Sciences NATURE PHYS-ORG
Ancient indigenous New Mexican community knew how to sustainably coexist with wildfire
Credit: Christopher Roos Wildfires are the enemy when they threaten homes in California and elsewhere. But a new study led by SMU suggests that people...
ADVENTURE NATURE TO TRAVEL
French Polynesia, discover dream beaches
French Polynesia (/ˈfrɛntʃ pɒlɪˈniːʒə/ (About this soundlisten); French: Polynésie française ; Tahitian: Pōrīnetia Farāni), officially the Collectivity of French Polynesia, is an overseas collectivity of...
ENVIRONMENTAL PROTECTION MIXED NATURE
Global Forest Watch Tracks Deforestation in Real Time – And Helps Fight It Too
Global Forest Watch's satellite-based maps provide users with access to data on forests worldwide - and are an important tool in the fight against forest...
ANIMALS NATURE PHYS-ORG
Jaguars robust to climate extremes but lack of food threatens species
Credit: Pixabay/CC0 Public Domain A new QUT-led study has found wild jaguars in the Amazon can cope with climate extremes in the short-term, but numbers...
ADVENTURE NATURE
What makes the world's biggest surfable waves?
On Feb. 11, 2020, Brazilian Maya Gabeira surfed a wave off the coast of Nazaré, Portugal, that was 73.5 feet tall. Not only was this...
Altice USA to Hold Conference Call to Discuss Q4 and FY 2020 Results
Canada's Flight Attendants Call for Action Plan From Trudeau Government for Airline Sector
United Kingdom (UK) Travel Insurance Market Dynamics and Opportunities Report 2020: Market is Expected to Contract by 58.2% Due to COVID-19 & Brexit – ResearchAndMarkets.com
MillionaireMatch Pushes Back Against False Claims That It Is for "Sugar Daddies"
Zynga to Discuss Fourth Quarter and Full Year 2020 Financial Results on February 10, 2021
Chatham Lodging Trust Announces Fourth Quarter Earnings Call to be Held on Wednesday, February 24, 2021
AMCI Acquisition Corp. Announces Special Meeting of its Stockholders to Consider Proposed Business Combination with Advent Technologies Inc.
Group Nine Acquisition Corp. Announces Closing of $230M Initial Public Offering, Including Full Exercise of the Underwriters' Over-Allotment Option
Q2 Holdings, Inc. Announces Investor Conference Call to Review Fourth Quarter and Full-Year 2020 Financial Results
ProAssurance Corporation Announces Dates for Fourth Quarter 2020 Results Release and Conference Call
ADVENTURE BUSINESS WIRE
Schutz für den Amazonas-Regenwald
Energiewende-jetzt
Ein historisches Abkommen zum Schutz des Lebensraums von Millionen Monarchfaltern
Unsere Ozeane spenden leben
Greenpeace in der Zukunftskommission Landwirtschaft
Partly in cooperation with
A PRIVATE BLOG MAGAZIN
© Copyright 2020 amazing4you.de